DiscoverRisk Never Sleeps PodcastEpisode #145. Cancer Isn’t One Size Fits All, Why Treatment Shouldn’t Be Either, with Jim Foote, CEO and Co-Founder of First Ascent Biomedical
Episode #145. Cancer Isn’t One Size Fits All, Why Treatment Shouldn’t Be Either, with Jim Foote, CEO and Co-Founder of First Ascent Biomedical

Episode #145. Cancer Isn’t One Size Fits All, Why Treatment Shouldn’t Be Either, with Jim Foote, CEO and Co-Founder of First Ascent Biomedical

Update: 2025-11-06
Share

Description

What if cancer treatment could be as unique as your own DNA?


In this episode, Jim Foote, CEO and Co-Founder of First Ascent Biomedical, shares how his company is transforming oncology through functional precision medicine, designing personalized cancer treatments tailored to each patient’s biology. He explains how this approach moves beyond population averages to improve outcomes and why technology and biology must work together to guide care. Foote also reflects on how losing his 17-year-old son to cancer inspired him to create better tools for doctors and patients alike, comparing cancer’s constant mutation to the evasiveness of cyber threats.


Tune in to hear how innovation, resilience, and data-driven care are redefining the future of cancer treatment!







For more information and ways to increase risk awareness and safety, visit us at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.censinet.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.


Music by ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠David Cosgrove⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ an accomplished composer, musician, producer, and engineer. Listen to his latest project ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Del Piombo⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.




Learn more about your ad choices. Visit megaphone.fm/adchoices

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Episode #145. Cancer Isn’t One Size Fits All, Why Treatment Shouldn’t Be Either, with Jim Foote, CEO and Co-Founder of First Ascent Biomedical

Episode #145. Cancer Isn’t One Size Fits All, Why Treatment Shouldn’t Be Either, with Jim Foote, CEO and Co-Founder of First Ascent Biomedical

Ed Gaudet